Novavax, Inc. (NASDAQ:NVAX) closed the Friday session strong right near the high of the day. I think this stock could see $150 next week. Last night after the market's close, the company announced that it has finalized an agreement with the Government of Canada to supply up to 76M doses of NVX-CoV2373, the company's recombinant protein-based COVID-19 vaccine. Canada has committed to purchase 52M doses of the vaccine with the option for up to an additional 24M doses. NVX-CoV2373 is currently in Phase 3 clinical development for the prevention of COVID-19. The company expects to supply NVX-CoV2373 to Canada beginning as early as the second quarter of 2021, following authorization by Canada's regulatory agency. Looking at the daily technical daily chart the near-term outlook is positive. Momentum indicators are starting to point up, which is a sign of growing strength in the stock and MACD is also giving a positive indication. NVAX will move quickly, so keep it on your screen on Monday.